These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
359 related articles for article (PubMed ID: 23546483)
1. Moving toward a more ideal anticoagulant: the oral direct thrombin and factor Xa inhibitors. King CS; Holley AB; Moores LK Chest; 2013 Apr; 143(4):1106-1116. PubMed ID: 23546483 [TBL] [Abstract][Full Text] [Related]
2. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future]. Dumont B; Faille D; Ajzenberg N Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670 [TBL] [Abstract][Full Text] [Related]
3. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era. Contractor T; Levin V; Martinez MW; Marchlinski FE Postgrad Med; 2013 Jan; 125(1):34-44. PubMed ID: 23391669 [TBL] [Abstract][Full Text] [Related]
4. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. Lip GY; Larsen TB; Skjøth F; Rasmussen LH J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324 [TBL] [Abstract][Full Text] [Related]
5. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions. Cheng JW; Barillari G J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983 [TBL] [Abstract][Full Text] [Related]
6. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban. Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583 [TBL] [Abstract][Full Text] [Related]
7. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. Graff J; Harder S Clin Pharmacokinet; 2013 Apr; 52(4):243-54. PubMed ID: 23389892 [TBL] [Abstract][Full Text] [Related]
8. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Mantha S; Ansell J Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145 [TBL] [Abstract][Full Text] [Related]
9. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398 [TBL] [Abstract][Full Text] [Related]
10. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials. Kakkos SK; Kirkilesis GI; Tsolakis IA Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420 [TBL] [Abstract][Full Text] [Related]
12. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation. Berman JP; Halperin JL Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966 [TBL] [Abstract][Full Text] [Related]
13. New oral anticoagulants for the treatment of venous thromboembolism. Agnelli G; Becattini C; Franco L Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903 [TBL] [Abstract][Full Text] [Related]
14. Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery. Quinlan DJ; Eriksson BI Best Pract Res Clin Haematol; 2013 Jun; 26(2):171-82. PubMed ID: 23953905 [TBL] [Abstract][Full Text] [Related]
15. New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation. Aguilar MI; Kuo RS; Freeman WD Neurol Clin; 2013 Aug; 31(3):659-75. PubMed ID: 23896498 [TBL] [Abstract][Full Text] [Related]
16. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Eriksson BI; Quinlan DJ; Eikelboom JW Annu Rev Med; 2011; 62():41-57. PubMed ID: 21226611 [TBL] [Abstract][Full Text] [Related]
17. New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities. Dobesh PP; Fanikos J Drugs; 2014 Nov; 74(17):2015-32. PubMed ID: 25300410 [TBL] [Abstract][Full Text] [Related]
18. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis. Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161 [TBL] [Abstract][Full Text] [Related]
19. Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal. Bauer KA Stroke; 2013 Jun; 44(6 Suppl 1):S38-40. PubMed ID: 23709725 [No Abstract] [Full Text] [Related]
20. Practical aspects of new oral anticoagulant use in atrial fibrillation. Undas A; Pasierski T; Windyga J; Crowther M Pol Arch Med Wewn; 2014; 124(3):124-35. PubMed ID: 24556890 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]